EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC

NCT05075577 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

77

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated early due to a lack of improved efficacy.

Conditions

Prostate Cancer

Interventions

DRUG: Enzalutamide
DRUG: EPI-7386 with Enzalutamide

Sponsor

ESSA Pharmaceuticals